Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Does imatinib turn recurrent and/or metastasized gastrointestinal stromal tumors into a chronic disease? - single center experience.

European journal of gastroenterology & hepatology - 1 Jul 2009

Armbrust Thomas, Sobotta Michael, Gunawan Bastian, Füzesi Laszlo, Langer Claus, Cameron Silke, Ramadori Giuliano

Abstract excerpt

BACKGROUND: Gastrointestinal stromal tumors (GIST) are mesenchymal tumors of the gastrointestinal tract supposed to arise from the cells of Cajal because of gain-of-function mutations of the tyrosine receptor kinases c-kit or platelet-derived growth factor receptor A. Imatinib selectively inhibits the kinase activity of both receptors. Despite this breakthrough in the treatment of GIST, resistance against...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzamides
Share to Chronic Disease

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gastrointestinal Stromal Tumors

Share to Imatinib Mesylate

Share to Piperazines

Share to Pyrimidines

Share to Receptors, Platelet-Derived Growth Factor

Share to Survival Analysis

Source

Identifiers

PMID: 19369884
DOI: 10.1097/MEG.0b013e32830b0f76

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Does imatinib turn recurrent and/or metastasized gastrointestinal stromal tumors into a chronic disease? - single center experience.PMID 19369884Read ↗

A review of resistance patterns and phenotypic changes in gastrointestinal stromal tumors following imatinib mesylate therapy.Semantic proximity Read ↗

Secondary C-kit mutation is a cause of acquired resistance to imatinib in gastrointestinal stromal tumor.Semantic proximity Read ↗

[GIST refractory to imatinib treatment].Semantic proximity Read ↗

GIST under imatinib therapy.Semantic proximity Read ↗

[Study on the mechanism of imatinib-induced resistance in gastrointestinal stromal tumors].Semantic proximity Read ↗

Rhabdomyosarcomatous differentiation in gastrointestinal stromal tumors after imatinib resistance: a potential diagnostic pitfall.Semantic proximity Read ↗

Resistance to treatment in gastrointestinal stromal tumours: what radiologists should know.Semantic proximity Read ↗

[Efficacy observation on imatinib reintroduction in gastrointestinal stromal tumor with high recurrence risk after imatinib adjuvant therapy failure].Semantic proximity Read ↗

[Origin of resistance to Imatinib mesylate: lessons learned from this experience].Semantic proximity Read ↗

Focal progression in patients with gastrointestinal stromal tumors after initial response to imatinib mesylate: a three-center-based study of 38 patients.Semantic proximity Read ↗

Imatinib escalation or sunitinib treatment after first-line imatinib in metastatic gastrointestinal stromal tumor patients.Semantic proximity Read ↗

Roots of imatinib resistance: a question of self-renewal?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.